Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

Less than two years af­ter Take­da inked a col­lab­o­ra­tion with Po­sei­da Ther­a­peu­tics to de­vel­op six liv­er-di­rect­ed and hematopoi­et­ic stem cell-di­rect­ed in vi­vo gene ther­a­pies, Take­da …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.